Aureus proposed over on IV that the trial population below for a sub-analysis of DECALRE TIMI-58 for those with previous MI could serve as a good proxy for BETonMACE placebo. 

Placebo group in those with prior MI in "Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial" had 3-point MACE rate of 17.8% at 4 years. This equates to about 4.45 events per 100 patient years. In this trial, median time from previous MI was 5.4 years and those w/ baseline eGFR of 60 mL/min were excluded. BETonMACE median time from ACS event is somewhere in the realm of 30 days, also has low-HDL requirement and allows patients with eGFR at baseline as low as 30 mL/min. EXAMINE and ELIXA are still better proxy's in my opinion with event rates in the 6 to 8 per 100 patient years. 

BearDownAZ